Ocular Therapeutix OCUL Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 87.2%-0.1pp | 87.3%-1.5pp | 88.9%-0.5pp | 89.4%-1.3pp | 90.7%-0.5pp | |
| Operating margin | -575.4%-55.7pp | -519.8%-70.1pp | -449.7%-47.1pp | -402.6%-60.5pp | -342.2%-72.6pp | |
| Net margin | -558.2%-46.3pp | -511.9%-64.3pp | -447.6%-65.1pp | -382.5%-59.4pp | -323.1%-19.4pp | |
| EBITDA margin | -566.5%-55.1pp | -511.4%-69.0pp | -442.4%-46.7pp | -395.7%-60.0pp | -335.7%-72.1pp | |
| Free cash flow margin | -463%-45.5pp | -417.5%-60.0pp | -357.5%-41.0pp | -316.5%-67.7pp | -248.8%-35.5pp | |
| Returns | ||||||
| Return on equity | -68.6%-13.7pp | -54.9%+27.0pp | -81.8%-18.4pp | -63.4%-6.2pp | -57.2%+38.0pp | |
| Return on assets | -51%-9.0pp | -42%+13.4pp | -55.4%-10.6pp | -44.8%-4.0pp | -40.8%+13.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Inventory turnover | 1.9×-0.1× | 2×-0.1× | 2.1×0.0× | 2.1×+0.2× | 1.9×-0.2× | |
| Liquidity | ||||||
| Current ratio | 14.8×-0.6× | 15.4×+7.5× | 7.9×-2.2× | 10.1×-0.1× | 10.2×-0.4× | |
| Quick ratio | 14.7×-0.6× | 15.3×+7.5× | 7.8×-2.2× | 10×-0.1× | 10.1×-0.5× | |
| Cash ratio | 14×-0.5× | 14.5×+7.5× | 7×-2.1× | 9.1×-0.1× | 9.2×-0.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×-0.2× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×-0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Interest coverage | -25.8×-2.9× | -22.8×-2.1× | -20.7×-2.2× | -18.5×-2.2× | -16.3×-3.7× | |
| Per Share | ||||||
| Book value per share | $2.60-25.7% | $3.49+149% | $1.40-20.8% | $1.77+12.9% | $1.57-21.2% | |
| Valuation | ||||||
| Market capitalization | $1.84B-28.7% | $2.59B+27.2% | $2.03B+40.5% | $1.45B+24.2% | $1.17B-13.2% | |
| Enterprise value | $1.26B-34.8% | $1.93B+9.1% | $1.77B+55.8% | $1.13B+27.1% | $892.18M-13.1% | |
| Price / sales | 35.4×-14.4× | 49.8×+13.3× | 36.5×+10.9× | 25.6×+6.0× | 19.5×-1.5× | |
| Price / book | 3.2×-0.8× | 4×-3.9× | 7.9×+3.1× | 4.7×+0.4× | 4.4×+0.1× | |
| EV / sales | 24.1×-12.9× | 37.1×+5.4× | 31.7×+11.7× | 20×+5.1× | 15×-1.1× | |
| Free cash flow yield | -13.1%-4.7pp | -8.4%+1.4pp | -9.8%+2.6pp | -12.4%+0.3pp | -12.7%-2.6pp | |
| Earnings yield | -15.8%-5.5pp | -10.3%+2.0pp | -12.3%+2.7pp | -15%+1.6pp | -16.5%-2.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ocular Therapeutix's profit margins?
- Ocular Therapeutix (OCUL) runs a 87.2% gross margin and a -575.4% operating margin, with a -558.2% net margin.
- Where do Ocular Therapeutix's ratios come from?
- Every ratio is computed from Ocular Therapeutix's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.